Skip to content
DataLookout
Menu

NCT06637007

Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

The efficacy of the investigational drug will be determined by the objective tumor evaluation conducted by the research center based on the RECIL 2017 lymphoma efficacy evaluation criteria
Timeframe: Baseline and testing every 6 weeks

Arms and interventions

Chidamide Tablets combined with AK112Experimental

1. Medication dosage:Chidamide Tablets(30mg,Twice a week,po),AK112(Once every 3 weeks). If you experience any discomfort during the medication process, please inform your responsible doctor in a timely manner. He/she will provide appropriate treatment based on the severity of the reaction. In severe cases, the dosage of medication will be adjusted until it is stopped. 2. Medication method: The interval between two oral doses of Xidabenzamide should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), and should be taken 30 minutes after breakfast. During the research process and before the end of medication, the responsible doctor will conduct physical and laboratory examinations on you in accordance with the experimental protocol to evaluate the impact of the experimental drug on you.

Drugs: Chidamide Tablets combined with AK112

Sites

1 site in 1 country

  • Shanxi Cancer HospitalTaiyuan, Shanxi, China